- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01424540
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
A Randomized, Double Blind, Single Dose, Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 in Healthy Adult Volunteers
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New York
-
Buffalo, New York, Verenigde Staten, 14202
- GSK Investigational Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin less than or equal to 1.5xUpper Limit of Normal (ULN).
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including [medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included at the discretion of the Investigator only if the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
- Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
- A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, oophorectomy, or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea.
Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow up visit.
- Body weight greater than or equal to 50 kilogram (kg) for men and 45 kg for women. Body mass index (BMI) between 18.5-30 inclusive will be allowed.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- Subject has demonstrated an adequate echocardiographic window.
- QTcB less than 450 milliseconds (msec).
Exclusion Criteria:
- A positive pre-study Hepatitis B surface antigen,positive Hepatitis C antibody, or a positive test for HIV antibody result within 3 months of screening.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- History of regular alcohol consumption within 6 months of the study.
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mililiters within a 56 day period.
- Pregnant females as determined by positive [serum or urine] hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Subjects who have asthma or a history of asthma.
- Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice [and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices] from 7 days prior to the first dose of study medication.
- Left ventricular ejection fraction less than 55% at screening.
- The subject's systolic blood pressure is outside the range of 90-140, or diastolic blood pressure is outside the range of 45-90 or heart rate is outside the range of 50-100beats per minute for female subjects or 45-100 beats per minute for male subjects.
- Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination):
Males-Heart rate less than 45 and greater than 100 beats per minute (bpm). Females-Heart rate less than 50 and greater than 100 bpm Evidence of previous myocardial infarction (Does not include ST segment changes associated with repolarization).
Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome). Sinus Pauses greater than 3 seconds. Any significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety for the individual subject. Non-sustained or sustained ventricular tachycardia ( greater than or equal to 3 consecutive ventricular ectopic beats).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Treatment A
GSK2336805 150mg
|
Single Dose
|
Placebo-vergelijker: Treatment B
GSK2336805 Placebo
|
Single Dose
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of subjects with a change in ejection fraction greater than 10 percent
Tijdsspanne: 10 hours
|
Echocardiographic measures of contractility
|
10 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Number of subjects with electrocardiogram (ECG) parameters out of range
Tijdsspanne: 3 hours
|
Cardiovascular measures
|
3 hours
|
Number of subjects with vital signs out of range
Tijdsspanne: 24 hours
|
Cardiovascular measures
|
24 hours
|
Number of subjects with adverse events
Tijdsspanne: 24 hours
|
tolerability
|
24 hours
|
Number of subjects using concurrent medication
Tijdsspanne: 24 hours
|
Concomitant medications
|
24 hours
|
Number of subjects with laboratory values out of range
Tijdsspanne: 24 hours
|
Labs
|
24 hours
|
Area under the curve (0-24)
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Maximum observed concentration (Cmax)
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Terminal phase half-life
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Lag time before observation of drug concentrations in sampled matrix
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Time of occurrence of Cmax
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Concentration at 24 hours
Tijdsspanne: 24 hours
|
PK parameter
|
24 hours
|
Correlation between concentration and various safety parameters
Tijdsspanne: 24 hours
|
Safety, PK
|
24 hours
|
B-type natriuretic peptide (BNP) lab result
Tijdsspanne: 24 hours
|
Cardiac biomarkers
|
24 hours
|
Troponin lab results
Tijdsspanne: 24 hours
|
Cardiac biomarkers
|
24 hours
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 115535
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatitis C
-
Trek Therapeutics, PBCVoltooidChronische Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C virale infectieVerenigde Staten, Nieuw-Zeeland
-
Trek Therapeutics, PBCVoltooidChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C virale infectieVerenigde Staten
-
Beni-Suef UniversityVoltooidChronische hepatitis C-virusinfectieEgypte
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIngetrokkenChronische hepatitis C-virusinfectieIsraël
-
Hadassah Medical OrganizationOnbekendChronische hepatitis C-virusinfectieIsraël
-
Humanity and Health Research CentreBeijing 302 HospitalVoltooidChronische hepatitis C-infectieChina
-
Tripep ABInovio PharmaceuticalsOnbekendChronische hepatitis C-virusinfectieZweden
-
AbbVieVoltooidChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
AbbVieVoltooidChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
University Health Network, TorontoVoltooidChronische hepatitis C-infectieCanada
Klinische onderzoeken op GSK2336805 150mg
-
PfizerVoltooid
-
Yuhan CorporationVoltooidGezonde vrijwilliger | NierstoornissenKorea, republiek van
-
The Affiliated Hospital of Qingdao UniversityVoltooidGezonde vrijwilligersChina
-
Hepion Pharmaceuticals, Inc.VoltooidNASH met fibroseVerenigde Staten
-
Green Cross CorporationC&R Research, Inc.; CRScubeOnbekendGastritisKorea, republiek van
-
Warner ChilcottVoltooidPostmenopauzale OsteoporoseVerenigde Staten
-
Novartis PharmaceuticalsWervingNiet-kleincellig longcarcinoomIndië
-
YD Global Life Science Co., Ltd.OnbekendDiabetisch macula-oedeem (DME)Verenigde Staten, Korea, republiek van
-
GlaxoSmithKlinePPDVoltooidHepatitis C, chronischPuerto Rico, Verenigde Staten